US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by NextCure
< Previous
1
2
Next >
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
August 06, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
July 14, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
June 04, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
June 01, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
May 07, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
May 04, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
April 21, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
April 07, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
March 31, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
March 05, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update
January 23, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
November 20, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
November 17, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
November 12, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
November 05, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
October 16, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 04, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
August 07, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
July 24, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
June 16, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
May 29, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
May 01, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
April 04, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
March 06, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
January 10, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Announces Acceptance of IND Application for LNCB74
December 10, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 26, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
November 19, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
November 05, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
< Previous
1
2
Next >
